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INTRODUCTION 
 Nearly one third of the world's population have been infected  with 
hepatitis B and the virus is endemic in many Asian  countries. In India 4-
4.75 per cent carry the virus.(1). 
 Hepatotrophic virus associated with acute and chronic hepatitis are 
TABLE 1  -- The Hepatitis Viruses 
Virus Hepatitis A Hepatitis B 
Hepatitis 
C Hepatitis D 
Hepatitis 
E 
Type of 
virus 
ssRNA partially 
dsDNA 
ssRNA Circular 
defective 
ssRNA 
ssRNA 
Viral family Hepatovirus; 
related to 
picornavirus 
Hepadnavirus Flaviridae Subviral 
particle in 
Deltaviridae 
family 
Calicivirus
Route of 
transmission 
Fecal-oral 
(contaminated 
food or water)
Parenteral, 
sexual 
contract, 
perinatal 
Parenteral; 
intranasal 
cocaine 
use is a 
risk factor
Parenteral Fecal-oral 
Mean 
incubation 
period 
2–4 weeks 1–4 months 7–8 weeks Same as HBV 4–5 weeks
Frequency 
of chronic 
liver disease 
Never 10% ׽80% 5% 
(coinfection); 
≤70% for 
superinfection 
Never 
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Virus Hepatitis A Hepatitis B 
Hepatitis 
C Hepatitis D 
Hepatitis 
E 
Diagnosis Detection of 
serum IgM 
antibodies 
Detection of 
HBsAg or 
antibody to 
HBcAg 
PCR for 
HCV 
RNA; 3rd-
generation 
ELISA for 
antibody 
detection 
Detection of 
IgM and IgG 
antibodies; 
HDV RNA 
serum; HDAg 
in liver 
PCR for 
HEV 
RNA; 
detection 
of serum 
IgM and 
IgG 
antibodies 
 
 Hepatitis B , the cause of serum hepatits,is the most versatile of 
hepatotropic viruses. 
HBV can produce 
(1) Acute hepatitis 
(2) Chronic non progressive hepatitis 
(3) Progressive chronic disease ending in cirrhosis 
(4) Fulminant hepatitis with massive liver necrosis 
(5) An asymptomatic carrier state 
 HBV is present in the blood for the last stages of incubation period 
of 30-180 days and during the active episodes of acute and chronic 
hepetits and is present in all physiological and pathological body fluids 
with the exception of stools. HBV is a hardy virus and can withstand 
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extremes of temperature and humidity. Thus although blood and body 
fluids are the primary vehicles of transmission, virus may also spread by 
contact with body secretions such as semen, saliva, sweat, tears, breast 
milk and pathological effusions. Tansfusions, blood products, dialysis, 
needle stick accidents among the health care workers, intravenous drug 
abuse and sexual constitute the primary risk categories for HBV 
infection. In one third of the patient source of infection is unknown. 
Outcomes of HBV infection: 
 Approximately 70% of the patients have mild or no symptoms and 
do not develop jaundice.the remaining 30% have  constitutional 
symptoms such as anorexia , nausea, fever with jaundice and right upper 
quadrant pain. Almost all cases resolve spontaneously without treatment 
and is self limiting. Chronic disease rarely occurs in an adult in non 
endemic areas. Fulminant hepatitis is also rare about 0.5-1%. 
 HBV was first linked to hepatitis in the 1960s when Australia 
antigen (later known as HBV surface antigen) was identified.[25 The virus 
is a member of the Hepadnaviridae, a family of DNA viruses that cause 
hepatitis in multiple animal species. There are eight HBV genotypes with 
geographic distribution around the globe. The mature HBV virion is a 42-
nm, spherical double-layered “Dane particle” that has an outer surface 
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envelope of protein, lipid, and carbohydrate enclosing an electron-dense, 
28-nm, slightly hexagonal core. The genome of HBV is a partially 
double-stranded circular DNA molecule having 3200 nucleotides ( Fig. 
18-10 ). The HBV genome contains four open reading frames coding 
for:[26]  
   
•    A nucleocapsid “core” protein (HBcAg, hepatitis B core antigen) 
and a longer polypeptide transcript with a precore and core region, 
designated HBeAg (hepatitis B “e” antigen). The precore region 
directs the HBeAg polypeptide toward secretion into blood, 
whereas HBcAg remains in hepatocytes for the assembly of 
complete virions. 
   
•    Envelope glycoproteins (HBsAg, hepatitis B surface antigen), 
which consist of three related proteins: large HBsAg (containing 
Pre-S1, Pre-S2, and S), middle HBsAg (containing Pre-S2 and S), 
and small HBsAg (containing S only). Infected hepatocytes are 
capable of synthesizing and secreting massive quantities of 
noninfective surface protein (mainly small HBsAg). 
   
•    A polymerase (Pol) that exhibits both DNA polymerase activity 
and reverse transcriptase activity. Genomic replication occurs via 
an intermediate RNA template, through a unique replication cycle: 
DNA ➙ RNA ➙ DNA. 
   
•    HBx protein, which is necessary for virus replication and may act 
as a transcriptional transactivator of the viral genes and a wide 
variety of host genes. It has been implicated in the pathogenesis of 
liver cancer in HBV infection.
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Clinical course of the infection: 
natural course of the disease can be followed by serum markers ( 
18-11 ).  
   •    HBsAg appears before the onset of symptoms, peaks during overt 
disease, and then declines to undetectable levels in 3 to 6 months. 
   
•    Anti-HBs antibody does not rise until the acute disease is over and 
is usually not detectable for a few weeks to several months after the 
disappearance of HBsAg. Anti-HBs may persist for life, conferring 
protection; this is the basis for current vaccination strategies using 
noninfectious HBsAg. 
   
•    HBeAg, HBV-DNA, and DNA polymerase appear in serum soon 
after HBsAg, and all signify active viral replication. Persistence of 
HBeAg is an important indicator of continued viral replication, 
infectivity, and probable progression to chronic hepatitis. The 
appearance of anti-HBe antibodies implies that an acute infection 
has peaked and is on the wane. 
   
•    IgM anti-HBc becomes detectable in serum shortly before the onset 
of symptoms, concurrent with the onset of elevated serum 
aminotransferase levels (indicative of hepatocyte destruction). Over 
a period of months the IgM anti-HBc antibody is replaced by IgG 
anti-HBc. As in the case of anti-HAV, there is no direct assay for 
IgG anti-HBc, but its presence is inferred from decline of IgM anti-
HBc in the face of rising levels of total anti-HBc. 
 
 With increasing life expectancy and the expected  global  increase 
in cancer, chemotherapy induced reactivation of hepatitis B is likely to 
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become an increasing problem.hepatitis B reactivation may occur in up to 
50% of patients with lymphoma without prophylaxis and in up to 40% of 
breast cancer patients with positive serology.2. reactivation hepatitis may 
be fatal if it is not recognized and treated immediately. Preemptive 
treatment with Lamivudine is effective before chemotherapy for 
prophylaxis and treating active infection in some cases. Several risk 
factors have been proposed for reactivation of hepatitis B such as 
hematological malignancy, younger age, male gender and high pretherapy 
HBV-DNA levels.3.  Patients with significant levels of hepatitis B virus 
(HBV) DNA in serum prior to chemotherapy and patients receiving 
intensive chemotherapy for hematological malignancies appear 
particularly  more at risk.  
 Anthracyclines and steroids are among the chemotherapeutic 
agents most aften reported to be associated with reactivation of hepatitis. 
There are many chemotherapeutics that have been reported to cause 
reactivation hepatitis. Serum levels of aminotransferases,bilirubin , 
serological markers and HBV-DNA levels are important for hepatitis 
reactivation.  Most patients who suffer reactivation of  hepatitis B are 
positive  for hepatitis B surface antigen (HBsAg)  prior to chemotherapy  
and are therefore easily identifiable by routine screening. In addition,the 
very large population of patients who have been exposed to the virus and 
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have apparently cleared the virus as assessed by serological testing 
(HbsAg negative/hepatitis B core antibody [HBcAb] positive) may also 
be at risk of reactivation. These patients should be monitored and in some 
cases receive prophylaxis during chemotherapy. 
 Published experience with antiviral prophylaxis has largely been 
limited to the nucleoside analogue, lamivudine. The commencement of 
antiviral prophylaxis prior to chemotherapy and its continuation until 
restitution of normal host immunity is the cornerstone to effective 
prevention of hepatitis B reactivation. Though most of the studies are 
about hematological malignancies, there is much to be learned about solid 
tumors and hepatitis reactivation. 
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REVIEW OF LITERATURE 
 It is estimated that 2 billion people worldwide have been infected 
with the hepatitis B virus (HBV) and over 350 million are chronic 
carriers. The regional prevalence of chronic HBV varies widely. In areas 
of high endemicity in the Asia-Pacific region, it approaches 20%, whilst 
in south india the incidence of hepatitis B infection is about 4.5-5%.(1). 
 Patients who have been infected with HBV are vulnerable to 
disease reactivation during immunosuppressive  pharmacotherapy. The 
clinical consequences vary from asymptomatic  elevation of hepatic 
enzymes to severe hepatitis and death from  fulminant hepatic failure. In 
addition to the direct harm caused by HBV  reactivation, patient care may 
be compromised because of the need to  delay or prematurely cease 
chemotherapy.(4)  
Clinical significance of reactivation: 
 The likelihood of chronicity after acute hepatitis  varies as a 
function of age. Infection at birth is associated with clinically  silent acute 
infection but a 90% chance of chronic infection. Infection in  young 
adulthood in immunocompetent  persons is typically associated  with 
clinically apparent acute infection but risk of chronicity of only  
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approximately 1%. Most cases of chronic hepatitis B among adults ,  
however, occur in patients who never had a recognized episode of  
clinically apparent acute viral hepatitis.(5) 
 Degree of liver injury in patients with chronic  hepatitis B is 
variable ranging from none in inactive carriers to mild to  severe. Among 
adults with chronic hepatitis B, histologic features are of  prognostic 
importance.(6). HBV reactivation can be asymptomatic. 
 In patients who have previously achieved immune control of HBV, 
immunosuppressive therapy may allow viral replication to escape, 
resulting in spread of infection within the liver and an increase in 
circulating HBV DNA. Following completion of immunosuppressive 
therapy, restoration of the host's immune response may lead to an 
immune clearance-like response that results in widespread cytotoxic T 
cell-mediated lysis of infected hepatocytes and severe liver injury. This 
syndrome of so-called ‘Hepatitis B reactivation following chemotherapy’ 
has been recognized. 
 Reactivation largely occurs in patients with chronic hepatitis B 
(CHB) who are positive for hepatitis B surface antigen (HBsAg), but it 
can also affect previously infected patients who have apparently cleared 
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the virus. These patients can be identified serologically by the presence of 
hepatitis B core antibody (HBcAb) in the absence of HbsAg. 
Diagnosis: 
 Early studies of hepatitis B reactivation were hindered by a lack of 
uniformity in case definition and the relative insensitivity of previous 
methods used to measure viral replication. The current generally accepted 
definition of HBV reactivation, or a flare following chemotherapy, is the 
development of hepatitis with a serum ALT greater than three times the 
upper limit of normal, (2,3,7) or the occurrence of hepatitis during or 
immediately after cytotoxic chemotherapy, accompanied either by an 
increase in HBV-DNA levels of ≥10-fold, or an absolute increase that 
exceeds 9log10copies/mL, in the absence of other systemic 
infections.(7,8) Thus, other than close monitoring before, during, and 
after chemotherapy, the sensitivity of the HBV DNA assays is crucial. 
The earlier branched DNA hybridization assay (Quantiplex HBV DNA 
assay; Chiron, Berkeley, CA) has a detection limit of 0.7 × 106 
copies/mL, whereas recent polymerase chain reaction assays have a lower 
detection limit of 300 copies/mL.(9). 
Clinical presentation: 
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 The clinical presentation of HBV reactivation can range from 
asymptomatic anicteric elevation of hepatic enzymes to fulminant 
hepatitis. Icteric hepatitis is said to occur if the serum bilirubin is greater 
than twice the upper limit of the normal bilirubin concentration (15 
mmol/L). Typically, there is an increase in HBV DNA during or shortly 
after a cycle of chemotherapy which precedes any elevation of ALT by 
up to 3 weeks.(2) HBV reactivation may present as acute hepatitis with 
symptoms of malaise and fatigue; the average ALT elevation is 300 IU/L 
but may reach into the thousands. Serum bilirubin may range from mild 
to marked elevations. 
 Male patients with baseline ALT levels greater than 200 IU/L are 
three times more likely to develop a reactivation than patients with lower 
ALT levels. The HBcAb-IgM (the marker for acute hepatitis B) is present 
in about 60% of patients. Although hepatitis B viral DNA is expected to 
be present in high concentrations, it may be absent in 50% of patients at 
the time of peak ALT levels. Reactivation of chronic HBV infection may 
last weeks to months. A patient's underlying liver disease usually worsens 
during reactivation, and if cirrhosis is present, decompensation may occur 
with ascites, variceal bleeding, and liver failure in about 10% with 
mortality rates of 5%-10%.  
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Risk factors: 
Virological factors: 
 Although hepatitis B e antigen (HBeAg) positivity in patients with 
cancer appears to be a risk factor(8,10,11) this has not been found to be 
universally the case. (12,13,14) .An increased risk has also been observed 
in the absence of HBeAg seropositivity, and this has been attributed to 
the presence of the precore/core promoter HBV mutants (i.e., HBeAg-
negative/hepatitis B e antigen–positive chronic hepatitis B 
infection).(15).This finding has also been associated with severe 
fulminant hepatitis.(12,13). 
 With sensitive assays such as real-time polymerase chain reaction, 
recent studies in patients undergoing conventional-dose and high-dose 
chemotherapy with HSCT have shown that high pre-chemotherapy HBV 
DNA load, defined as above 3 × 105 copies/mL, is associated with 
increased likelihood of developing reactivation.(16,17). 
Cancer type and treatment factors: 
 Several anticancer immunosuppressive agents have been associated 
with HBV reactivation (Table 3); these could be broadly categorized into 
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conventional cytotoxic agents(18,19,20) and biologic response modifiers 
with anti-B and -T monoclonal antibody therapies. 
 Among the former, corticosteroids and anthracyclines have been 
most frequently associated with the condition(2,3,8,,21)HBV DNA 
contains a glucocorticoid responsive element that has been reported to 
facilitate HBV replication,(23,24)  while anthracycline has been 
demonstrated in vitro to stimulate HBV DNA secretion from HepG2-
derived 2.2.15 cells in a dose-dependent manner.(25). 
 Reactivation rates of 48% have been reported in HBsAg positive 
patients treated with chemotherapy for lymphoma, with an associated 
mortality of 4%.17 Other studies report an incidence of HBV reactivation 
following chemotherapy for lymphoma between 24 and 67% and a 
mortality of 4–41%.(2,8,21,26) In part this very high incidence may be 
explained by the intensive chemotherapy necessary for lymphoma, but 
also  may be due to the relatively high prevalence of HBV infection 
observed in patients with this condition.(2,29,30,31) Patients receiving 
intensive cytoreductive therapy and high dose Chemotherapy prior to 
hematopoietic stem cell transplantation are also particularly susceptible to 
HBV reactivation, with rates approaching 50%.(32,33,34,35,36).The 
level of viral replication prior to chemotherapy appears the most 
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important risk factor for HBV recurrence in this group.(32) In patients 
receiving chemotherapy for non-hematological tumors, the highest rates 
of HBV reactivation have been reported in patients with breast cancer 
where the incidence ranges between 41 and 56%.(25,36) The rate of 
reactivation appears to be lower in patients treated for other solid tumors, 
ranging between 14 and 21% in different studies.(2,37,38)These 
differences are most likely due to the types of chemotherapy used for 
these conditions rather than the nature of the malignancy per se. 
 The recent introduction of therapeutic monoclonal antibodies 
against B and T lymphocytes such as rituximab (a chimeric mouse human 
monoclonal antibody against CD20+ malignant lymphoid cells) and 
alemtuzumab (a humanized monoclonal antibody against anti-CD52+ 
malignant lymphoid cells), used alone or in combination with cytotoxic 
therapy, has been associated with HBV reactivation.(39,40-43) In 
October 2004, the U.S. Food and Drug Administration reported a possible 
relationship between fulminant hepatitis and rituximab use. These agents 
have been found to induce profound and durable B and T cell 
depletion.(46,47)Although lysis of HBV-infected hepatocytes is mainly 
mediated by CD8+ cytotoxic T cell immunity, B cells may also act as 
antigen-presenting cells and prime cytotoxic T lymphocyte–specific 
responses in HBV infection.(48)The progressive B and T cell depletion 
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may also account for the increasing incidence of HBV reactivation in 
anti-HBs– and/or anti-HBc–positive patients undergoing chemotherapy 
with these agents . Among the 7 cases reported, 3 developed fatal hepatic 
failure despite lamivudine therapy, possibly related to the delay in 
antiviral administration, and another had persistent HBsAg positivity(45). 
 Reactivation of HbsAG negative and HBc antibody positive 
patients. In individuals with resolved HBV infection (i.e., HBsAg-
seronegative, anti-HBs–postive and/or hepatitis B core antibody [anti-
HBc]–positive), HBV replication has been shown to persist in the liver 
and in peripheral blood mononuclear cells.(50,51) Two reports described 
patients receiving conventional dose chemotherapy. In 1 report,(49) 12 of 
17 patients with hematological malignancies had dramatic reduction of 
anti-HBs titer, and 5 (30%) had evidence of seroreversion with 
reappearance of HBsAg—2 of whom had persistent HBsAg despite 
cessation of chemotherapy. The second report described 51 Chinese 
patients with lymphoma—9 of whom developed hepatitis, with 2 having 
raised HBV DNA during chemotherapy,resulting in a 4% HBV 
reactivation rate.(8) In both reports, hepatic impairment had been mild 
and no direct HBV-related mortality was observed. 
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Management  of reactivation                                                                                             
 Until recently, aggressive supportive therapy and discontinuation 
of cytotoxic chemotherapy has been the mainstay of treatment. Interferon, 
which has both antiviral and immunomodulatory functions, has been 
shown to control hepatitis during chemotherapy.(27)  
 However, the use of conventional interferon(83) may be limited by 
the possibility of fatal hepatitic flare via augmentation of the 
immunomediated destruction of hepatocytes. Lamivudine, a nucleoside 
analogue, has been shown to have substantial activity in chronic HBV 
infection.(53-58) Lamivudine has also been claimed to be effective in 
controlling viral replication during HBV reactivation(60,61)(82-84) 
thereby allowing individual patients to continue cytotoxic chemotherapy 
upon maintenance of a sufficient hepatic function.(60,62) Sustained 
HBeAg seroconversion and undetectable serum HBV DNA level for at 
least 3 months after the discontinuation of lamivudine therapy have also 
been observed in some patients who were initially HBeAg-
seropositive,(62) and the postulated mechanism has been a high immune 
response to HBV reactivation that allows elimination of covalently closed 
circular DNA in hepatocytes in conjunction with suppression of viral 
replication.Lamivudine has also been reported to be effective in cases of 
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hepatic decompensation during HBV reactivation(52,61) and in cases that 
involve a precore HBV mutant.(62,60)                                                                  
Prevention:                                                                                                            
 Lamivudine prophylaxis is an effective means of reducing the 
reactivation . many studies have proved the efficacy of the prophylactic 
lamivudine.(58-68). Most of the studies have favoured that lamivudine 
should be started prior to first dose of chemotherapy and should be 
continued atleast 6 months after chemotherapy , some studies have 
continued lamivudine for more that a year. 
 Inspite of prophylactic lamivudine, reactivation has been recorded 
in some of the studies.On the other hand, despite lamivudine, HBV-
associated mortality has been reported in up to 20% of the HBsAg-
positive patients treated(89). This has been postulated to be due to a delay 
in antiviral administration at a time when severe hepatic impairment with 
massive hepatic damage had already occurred  One potential means of 
minimizing the risk of HBV reactivation is the avoidance of 
corticosteroid therapy as part of (85)chemotherapeutic/antiemetic regimes 
in HBsAg carriers., (69,70) However, HBV reactivation may still occur in 
association with the use of other cytotoxic/immunosuppressive 
agents.(71) Furthermore, this may lead to suboptimal therapy and may 
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even jeopardize the patient's chance of cure. In a prospective study of 50 
patients with non-Hodgkin's lymphoma who were randomized to receive 
either the standard steroid- containing regimen; (85) (prednisolone 
/epirubicin/cyclophosphamide/etoposide) or a steroid-free regimen 
(epirubicin/cyclophosphamide/etoposide), whereas the cumulative 
incidence of HBV reactivation was significantly higher in the steroid-
containing study arm (73% vs. 38%; P = .03), patients in the steroid-free 
arm had a significantly lower rate of complete remission and shorter 
overall survival.(71) (88). 
 Leaw et al(72) reported that interferon administered from the start 
of chemotherapy prevented HBV reactivation in 13 lymphoma patients. 
However, using interferon-containing combination chemotherapy for 
patients with inoperable HBV-related hepatocellular carcinoma has not 
reduced the incidence of HBV reactivation.  
 Reviewing the literatures, incidence of reactivation of Hepatitis B 
virus is varying  according to malignacy and the chemotherapy schedules. 
 In one of the study at Dept of medical oncology at SELUCK 
University at Turkey,(74) retrospectic study, retrospectively examined 
about 1826 patients 95 patients were found to be Hepatitis B surface 
antigen positive,59 patients were eligible for the final analysis, 9 patients 
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had reactivation. They included 50 patients with solid malignancy and 9 
patients with hematological malignancy. All the patients were not on 
Lamivudine prophylaxis. Among the 9 patients who underwent 
reactivation lung cancer 3 patients, breast 2 patients , GIT malignancy 3, 
and Lymphoma 1 patient. All the patients received standard 
chemotherapy schedules with or without radiotherapy as per regimens. 
 In another study by Dr.Yeo et.al. (75) at dept clinical oncology at 
Chinese University of Hong Kong- studied the reactivation of hepatitis b 
virus among the breast cancer patients receiving chemotherapy. It was a 
prospective study. 
 The main objectives were to determine the incidence of HBV 
reactivation in breast cancer patients undergoing conventional 
chemotherapy; to investigate whether "serial HBV DNA monitoring" 
improves the accuracy of diagnosing HBV reactivation when compared 
with previous schema that only measured HBV DNA at the time of 
clinical hepatitis ("conventional monitoring"); and to assess the clinical 
consequences as a result of developing the condition. The secondary 
objective was to identify risk factors associated with this condition. Over 
an 18-month period, 41 patients were studied. Ten developed HBV 
reactivation by conventional monitoring criteria, but with serial HBV 
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DNA monitoring, seven additional patients were diagnosed when 
increased HBV DNA levels were detected before, but not concomitant 
with, clinical hepatitis. Thus, a total of 17 patients (41%) developed HBV 
reactivation. Premature termination of chemotherapy or delay in 
treatment schedules occurred in 71% of the patients who developed viral 
reactivation, as compared with 33% in  those who did not develop the 
condition (P = 0.019). No risk factors associated with the development of 
HBV reactivation could be identified. Serial monitoring of HBV DNA, in 
addition to liver function,increases the sensitivity of diagnosing of HBV 
reactivation. 
 In another study by Dr.YEO. et al  at dept of clinical oncology 
Hong Kong, about the reactivation of Hepatitis B virus in Hepatocellular 
Carcinoma patients underwent chemotherapy.The  prospective study was 
conducted to determine the incidence of HBV reactivation, the associated 
morbidity and mortality, and possible risk factors. About 102 HBsAg-
positive patients with inoperable HCC underwent systemic CT. Patients 
received either combination cisplatin, interferon, doxorubicin and 
fluorouracil (PIAF) or single-agent doxorubicin. They were followed up 
during and for 8 weeks after CT.  In 102 patients, 59 (58%) developed 
hepatitis amongst whom 37 (36%) were attributable to HBV reactivation. 
Twelve (30%) died of HBV reactivation. CT was interrupted in 32 
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patients (86%) with reactivation and 54 (83%) without reactivation (P > 
0.05). The median survivals were 6.00 and 5.62 months, respectively (P = 
0.694). Elevated baseline alanine aminotransferase (ALT) was found to 
be a risk factor. 
 The study concluded as  HBV reactivation is a common cause of 
liver damage during CT in HBsAg-positive HCC patients. The only 
identifiable associated risk factor was elevated pre-treatment ALT. 
                                       A case was presented in the journal of breast 
cancer about the  reactivation of hepatitis B virus in a breast cancer 
patient receiving CAF chemotherapy. A 68 year old patient a case of 
breast cancer received adjuvant chemotherapy CAF regimen without 
steroids. On day 27 , patient developed reactivation of hepatits b virus. 
Patient was treated with symptomatic management and interferon with 
steroids and entecavir. But patient died of reactivation. 
 In another study done at Iran research centre of gastroenterology 
and liver disease at Tehran studied about the impact of 
immunosuppression and chemotherapy  on  reactivation of hepatitis B 
virus, concluded that Chemotherapy drugs, biological medications that 
are used to treat cancer, may cause hepatic side effects. Patients with pre-
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existing viral hepatitis may be more susceptible to exacerbation of their 
underlying liver disease, and risk of drug-induced hepatotoxicity. They  
conducted a search on immunosuppression, and its impact on reactivation 
of viral hepatitis, using the electro-nic medical databases.Before starting 
chemotherapy, it is recommended to record the past history of liver 
disease and check for hepatitis B virus (HBV) and hepatitis C virus 
(HCV) serology. In immunosuppressed patients,radiation toxicity, graft 
versus host disease, hepatic veno-occlusive disease, acalculous 
cholecystitis, tumor infiltration, ischemia, other viruses such as CMV and 
herpes virus, and systemic infection should also be considered. 
Transplant recipients with serologic evidence of previous infection with 
hepatitis B or C, or those who receive organs from a seropositive donor, 
should have viral load levels monitored before and after transplantation 
and, may also require treatment. They believe that there is a role for 
prophylactic use of antiviral treatment in  
patients at risk for HBV reactivation. 
 A systematic review of the trials which conducted on the 
reactivation of Hepatitis b and chemotherapy and role of Lamivudine 
prophylaxis concluded as-                                   
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 This systematic review included prospective trials with lamivudine 
for prophylaxis against HBV reactivation in patients on chemotherapy. 
PubMed and MEDLINE databases were searched to identify suitable 
trials for inclusion in the analysis. Eligible trials were examined and 
variables (which included rates of hepatitis, HBV reactivation, HBV-
related mortality, mutations that confer lamivudine resistance and adverse 
events) were assessed. Hepatitis was defined as a greater than threefold 
increase in baseline aminotransferase levels to above the upper limit of 
normal (58 IU/l) or an absolute increase of 100 IU/l compared with 
baseline. HBV reactivation was defined as a 10-fold increase in HBV 
DNA levels compared with baseline or an absolute increase of >1 109 
copies/ml in HBV DNA levels. 
 The primary outcome measures were rates of hepatitis and HBV  
reactivation. Secondary outcome measures included adverse events, 
HBV-related mortality and mutations that conferred lamivudine 
resistance. 
Results 
 In total, 10 trials with 173 patients were included in the analysis 
(one randomized, controlled trial; four prospective trials with historical 
controls; five prospective case series). Nine trials were performed in adult 
  24
populations and one trial in a pediatric population. The dose of 
lamivudine was 100 mg daily in the adult studies and 3 mg/kg body 
weight daily in the pediatric study. Lamivudine prophylaxis was 
administered 7–19 days before chemotherapy in seven studies, and on the 
first day of chemotherapy in three trials. Lamivudine therapy ended on 
the last day of chemotherapy in one trial, 1–3 months after chemotherapy 
in seven trials and 1 year in two trials. Duration of follow-up ranged from 
2 months to 2 years after chemotherapy. The rate of hepatitis in patients 
who received lamivudine prophylaxis was 9.2% (range 0.0–20.0%) 
compared with 54.0% (range 33.0–67.0%) in patients who received 
placebo. The rate of HBV reactivation in patients who received 
lamivudine was 8.7% (0.0–24.0%) compared with 37.0% (range 29.0–
56.0%) in patients who received placebo. Three deaths related to HBV 
reactivation occurred (two patients on lamivudine and one patient on 
placebo).Three studies monitored the emergence of mutations that 
conferred lamivudine resistance, and one trial identified two mutant 
strains among 46 patients (4.9%). There were no adverse events that led 
to dosage limitation or cessation of treatment.                          
 Similarly in a study published in journal of liver in december 2004 
done by Dai. MS, Wu PF, Shvu RY, Lu JJ, Chao Ty regarding  Hepatitis 
B virus reactivation in breast cancer patients undergoing cytotoxic 
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chemotherapy and the role of preemptive lamivudine administration 
concluded that The test group consisted of 11 female patients with BC 
who were seropositive for hepatitis B surface antigen (HBsAg). Of these, 
10 patients were treated in an adjuvant setting and one for metastatic 
disease. Lamivudine was given from the start of chemotherapy and was 
maintained until 1 month after the last infusion of chemotherapy. The 
control group consisted of nine historical BC patients carrying HBV and 
received similar systemic chemotherapy without preemptive lamivudine. 
Variables including HBsAg, HBV envelope antigen, anti-HBV envelope 
antibody, serial serum alanine transaminase (ALT), quantitative HBV 
viral DNA analysis, and HBV-DNA precore promoter and precore 
sequence were monitored. All patients tolerated lamivudine well without 
development of evident HBV reactivation or overt hepatitis. Serum ALT 
remained unchanged without rebound hepatitis after cessation of 
chemotherapy and withdrawal of lamivudine. 
RATIONALE OF PROPOSED STUDY: 
 The incidence of reactivation of hepatitis b is well established in 
the management of hematological malignancies and high dose 
chemotherapy. The role of prophylactic lamivudine in the management of  
hematological malignancy with chemotherapy in the chronic inactive 
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hepatitis b infection with HBs Ag positive patients and also in patients 
with past history of Hepatitis b even without a chronic carrier state.(105) 
 This study is done to know the incidence of reactivation of 
hepatitis b virus in chronic carriers of HBsAg positive patients in the 
south Indian set up. This study will give a picture of reactivation of HBV 
in common malignancies such as carcinoma stomach , breast cancer and 
hepatocellular carcinoma treated with common chemotherapies such as 
cisplatin based or adriamycin based chemotherapy. Based on the study 
the role of prophylactic Lamivudine in the management of solid 
malignancies can be established which may be cost effective and 
decreases the morbidity and mortality associated with HBV 
reactivation.(96-102) 
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AIM OF THE STUDY 
In this study  
1. To determine the hepatitis B virus carrier state in patients receiving 
chemotherapy 
2. To determine the incidence of reactivation of chronic carrier HBs 
Ag positive patients who underwent chemotherapy . 
3. To assess the possibility of follow up of the carrier patients with 
serological and liver function tests  for reactivation of Hepatitis B 
virus.  
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SUBJECTS AND METHODS 
1.Inclusion criteria: 
1.1Among the patients reported at medical oncology department, 
1.1.1.Pathogically confirmed malignancy either by FNAC or biopsy 
histopathology report. 
1.1.2. patients with hepatocellular carcinoma- confirmed by image guided 
FNAC or USG/ CT imaging suggestive of HCC with elevated S.AFP. 
1.1.3.patients with malignancy planned for chemotherapy  
         - neoadjuvant chemotherapy 
         -adjuvant chemotherapy 
         - palliative chemotherapy- for metastatic and recurrent lesions. 
1.2. Performance status ECOG- 2{zubrod score} 
1.3. complete hemogram with in normal limits 
      WBC Tc- > 1,500cells/mm3 
      Platelets >1,00,000cells/mm3 
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      Hemoglobin> 10gm% 
     ( or corrected with packed cell transfusion) 
1.4. Renal function 
      Blood urea : < 40 mg% 
      S. Creatinine: < 1.2mg% 
1.5 Liver function test: 
Total bilirubin <2 mg% 
SGOT/SGPT: < 1.5 times the upper limit of normal 
S.ALP        : < 1.5 times the upper limit of normal  
1.5.Cardiac function   
       ECHO: ejection fraction > 60% 
       ECG: within normal limits 
1.6. Age > 18 yrs 
1.7. Viral markers : HBs Ag positive 
1.8. Signed specific consent form prior to study  
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2.EXCLUSION CRITERIA: 
2.1.  known case of HBs antigen positive without proof of malignancy 
2.2.  patients with proof of malignancy and HBs antigen positivity but 
not on chemotherapy as per the study protocol 
2.3. known case of HBs antigen positive patients already on 
T.Lamivudine prophylaxis. 
2.4.  previous or present history of other immunesuppressive drugs  
2.4.1.  patients already on steroids for other comorbid medical conditions  
and as a treatment of malignancy except dexamethasone used as 
antiemetic prophylaxis and treatment. 
2.4.2. patients already on T.cyclophosphamide, azathioprine, 
cyclosporine, etc 
2.5. patients with history of autoimmune disorders are excluded 
2.6. patients with history of uncontrolled diabetes mellitus, and history 
of congestive cardiac failure, chronic kidney disease. 
2.7.  patients with decompensated liver disease 
 Total bilirubin > 2 mg% 
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     Elevated SGOT/SGPT > 1.5x UNL 
     Elevated ALP  > 1.5x UNL 
     Low albumin < 4gm% 
     Albumin / globulin ratio reversal 
(imaging suggested of cirrhosis with coexisting liver sol suggestive of 
hepatocellular carcinoma and elevated tumor markers with normal LFT 
are included in the study) 
2.8.  coexisting viral infections such as human immune deficiency virus 
are excluded. 
2.9.  patients with history of jaundice within 6 months previous to 
chemotherapy are excluded. 
2.9. patients with coexisting HCV antibodies positive are excluded 
2.10. previous history of chemotherapy and radiotherapy. 
2.11. previous history of malignancy treated surgically other than 
included in the study (patients with history of malignancy 
previously treated with surgery only but not with chemotherapy or 
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radiotherapy now with metastatic or recurrent disease and planned 
for 1st line chemotherapy are included in the sudy) 
2.12. performance status > 3 
2.13. patients with evidence of malignancy planned for chemotherapy 
with HBs antigen positive patients but with anti HBc positive 
patients, HBe antigen positive and HBV DNA positive are 
excluded from the study. 
2.15  patients with severe and active comorbid medical and surgical 
conditions. 
2.16. pregnant and nursing mothers. 
2.17  age  < 18 yrs and > 65 yrs. 
2.18. patients requiring dose modification due to renal or hepatic 
dysfunction are excluded from the study. 
DATA COLLECTION: 
Individual patients data collected  included: 
1. Proof of malignancy 
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2.  Imaging with tumor markers ( specific for the individual 
malignancy) 
3.  Clinical features and symptoms  
4.  Clinical examination of the patient prior to chemotherapy and 
every chemotherapy cycles. 
5. Complete hemogram, blood sugar, s.electrolytes 
6.  Renal function test. 
7.  Liver function test. 
8. Serological markers for HBV, HCV, HIV 
9. (5),(6),(7),- are repeated prior to every chemotherapy cycles 
10.  Documentation of HBV reactivation by serological markers. 
METHODOLOGY OF THE STUDY: 
 All the patients who attended medical oncology opd with proof of 
malignancy were evaluated and staged with necessary investigation. 
Patients were planned for chemotherapy as per the recommendations and 
included in the study protocol. Patients then counseled for testing the 
serological markers of HBV, HCV and HIV.  
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 Patients were then routinely investigated with complete hemogram, 
renal function test and liver function test. Patients who were HIV positive 
and HCV positive were excluded from the study . Patients who were 
found to be positive for HBs antigen positive were evaluated for  further 
serological markers of HBV to rule out active infection or chronic active 
infection. 
 Patients were advised to undergo serological markers –HBe 
antigen, ANTI HBc antibodies and HBV DNA .  Patients found to be 
positive for any of the above markers were excluded from the study as 
they have chronic active infection or acute infection . 
 Patients who were  not fit for chemotherapy as per complete 
hemogram, renal function test, liver function tests, are excluded from the 
study. Patients were counseled about the nature of study and requested to 
give informed written consent for the study.  
 Then patients were included in the study and were investigated 
with prechemo investigations necessary for the chemotherapy schedule. 
Patients were treated with chemotherapy as per the study protocols. 
Patients were advised to do complete hemogram ,renal function test and 
liver function test prior to every chemotherapy cycle. Patients with low 
WBC total count or absolute neutrophil count were treated with inj. G-
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CSF till count normalized and then started on next cycle chemotherapy. 
Patients with low hemoglobin and low platelet count were treated with 
packed cell transfusions and concentrated platelet transfusions.                      
Till then chemotherapy  was delayed   Patients with elevated renal 
parameters were evaluated for further renal function test to rule out pre 
renal or intra renal failure. If patient had prerenal failure treated 
symptomatically till the serum creatinine and blood urea normalized and 
then started on chemotherapy. Patients with intra renal failure were 
treated for the same and are excluded from the study as dose modification 
were not allowed as per study. 
 All the patients included in the study were evaluated for the liver 
function serially prior to every chemotherapy cycle. Patients who found 
to have elevated bilirubin or SGOT / SGPT or S.ALP. or GGT were 
investigated further to rule out reactivation. Patients were again 
reevaluated with serological markers HBe antigen, ANTI HBc antibodies 
and HBV DNA. Patients who were positive for any of the above markers 
were taken as reactivation of the hepatits B virus. 
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CHEMOTHERAPY SCHEDULES in THE STUDY: 
1. BREAST CANCER: 
Treated with FAC 
Inj . 5- Fluro uracil 500mg/m2 i.v. 
Inj. Adriamycin      50mg/m2 i.v. 
Inj. Cyclophosphamide 500mg/m2 i.v. 
Every 21 day cycle 
2.  LUNG CANCER: 
         Treated with P.E. 
         Inj . Cisplatin 80mg/m2 divided in three divided doses. D1-D3.i.v. 
         Inj.  Etoposide 100mg/m2 D1-D3. i.v. 
        Every 28 day cycle 
3.  CARCINOMA of STOMACH: 
         Treated with cisplatin and 5-FU 
         Inj. Cisplatin 25 mg/m2 D1-D3,i.v. 
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         Inj. 5-flurouracil 750mg/m2 D1-D3 , i.v. 
    Every 28 day cycle  
4. CA. ANAL CANAL. 
         Treated with cisplatin and 5-FU 
         Inj. Cisplatin 100mg/m2 in divided doses given in D1-D3.i.v. 
         Inj. 5- flurouracil 1000mg/m2 D1-D3. i.v. 
         Every  28 day cycle. 
5. CARCINOMA of OVARY: 
        Treated with cisplatin and cyclophosphamide 
        Inj. Cisplatin 100mg/m2 in divided doses in D1-D3. i.v. 
        Inj. Cyclophosphamide 600 mg/m2 D1. i.v. 
        Every 28 day cycle. 
6. OSTEOSARCOMA: 
        Treated with cisplatin , adriamycin and cyclophosphaminde 
        Inj. Cisplatin 100mg/m2 in divided doses D1-D3 .i.v. 
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        Inj. Adriamycin 25mg/m2 D1-D3.i.v. 
        Inj. Cyclophosphamide 400mg/m2 D1-D3.i.v. 
        Every 28 day cycle. 
7. CARCINOMA of ESOPHAGUS: 
          Treated with cisplatin and 5-Fu 
          Inj. Cisplatin 60mg/m2 in divided doses D1-D3. i.v. 
          Inj. 5-Fluro Uracil 750mg/m2 D1-D3.i.v. 
          Every 21 day cycle. 
8.RENAL CELL CARCINOMA: 
        Treated with gemcitabine and vinblastine 
        Inj. Gemcitabine 1000mg/m2 .   D1,D8,D15. i.v. 
        Inj. Vinblastine 8mg/m2 D1.i.v. 
        Every 21 day cycle. 
9. SECONDARIES LIVER with UNKNOWN PRIMARY: 
       Inj. Cisplatin 60mg/m2 in divided doses D1-D3. i.v. 
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       Inj. 5- flurouracil 750 mg/m2 D1-D3. i.v. 
10. CARCINOMA COLON: 
       Treated with FOLFOX-4 
       Inj oxaliplatin 85 mg/m2 i.v. D1. i.v. 
       Inj. 5- flurouracil 1000mg/m2 D1 & D2. i.v. 
      Inj. Leucovorin 200mg/m2 D1 & D2. i.v. 
       Schedule repeated every 14 days. 
11. PERIAMPULLARY CARCINOMA: 
     Treated with cisplatin and gemcitabine 
     Inj. Cisplatin 60 mg/m2 in divided doses D1-D3. i.v. 
     Inj. Gemcitabine 1.2gm/m2 D1, D8, D15. i.v. 
     Every 21 day cycle.  
12. HODGKINGS LYMPHOMA: 
     Inj. Adriamycin  25mg/m2 i.v. D1 & D15 
     Inj .Bleomycin 10U/m2   i.v. D1-D15 
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     Inj. Vinblastine 6 mg/m2 .i.v. D1-D15 
     Inj. Dacarbazine 375mg/m2. i.v. D1-D15 
     Every 28 day cycle. 
13. HEPATOCELLULAR CARCINOMA: 
     Inj. Cisplatin 60mg/m2 in divided doses D1-D3. i.v 
     Inj. Adriamycin 60 mg/m2 D1. .i.v. 
     Inj. 5- fluro uracil 750 mg/m2 D1-D3. i.v.  
     Every 21 day cycle. 
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RESULTS AND ANALYSIS 
 Between June 2009 and December 2010 all the patients registered 
at medical oncology opd GGH were evaluated for the serological status. 
All the patients underwent serology tests ELISA for HIV, ELISA for HBs 
AG and ELISA for Anti HCV antibodies. Totally 1850 patients were 
examined among them 62 patients were found to be HBS antigen 
positive. The HBS antigen positive patients are about 3.35% of the total 
patients underwent serological tests. 
 There were about 20 female patients and 42 male patients were 
diagnosed as hepatitis b antigen positive .Among the 62 patients  one 
patient had coexisting HIV infection and not included in the study, one 
patient had coexisting HCV antibodies positive  and hence not included 
in the study. Among the 60 patients only 43 patients had met the 
eligibility criteria for the study and included in the study. Those 17 
patients who do not met the criteria for the study 11 patients presented 
with jaundice and 3 patients had chronic renal disease and 2 patients had 
congestive cardiac failure and not included in the study. One patient had 
rheumatoid arthritis and already on steroids  and excluded.  Among the 
11 patients with jaundice 8 patients were diagnosed as hepatocellular 
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carcinoma and 2 were carcinoma stomach with liver secondaries and one 
with carcinoma pancreas with liver secondaries. 
Table 1: 
1. No of patients screened 1850 
2. No of patients HBs Antigen +ve 62 
3. No of patients eligible for study 43 
4. Patients excluded from the study 19 
 1.Patient with associated HIV  1 
 2. Patient with associated HCV 1 
 3.Patietns presented with jaundice 
Hepatocellular carcinoma 
Carcinoma stomach with liver sec 
Carcinoma pancreas with liver sec 
11 
8 
2 
1 
 4. Patients with CKD 3 
 5.Patients with CCF 2 
 6. Patient with rheumatoid arthritis 
already on steroids  
1 
 
  Within the 43 patients 3 patients developed elevated blood urea  
and serum creatinine and nephrologist advised to stop cisplatin and hence 
excluded from the study. None underwent dialysis and managed 
conservatively. Two patients developed severe grade 4 mucositis and 
febrile neutropenia while on adriamycin based chemo and one patient 
died of septic complications. Atlast 38 patients in the study  were 
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examined and monitored for the reactivation of HBV during 
chemotherapy taken for the study. 
Table 2: 
S.No. Maliganancy No of patients in the 
study 
1. Carcinoma stomach 9 
2. Carcinoma lung 8 
3. Carcinoma breast 7 
4. Hepatocellular carcinoma 5 
5. Hodgkins lymphoma 2 
6. osteosarcoma 2 
7. Carcinoma colon 2 
8. Carcinoma ovary 2 
9. Sec neck and sec liver unknown 
primary 
Each 1 (2) 
10. Renal cell ca, Ca anal canal, RCC, 
Periamp ca 
Each 1 (4) 
 total 43 
 Patients excluded from the study 
because of discontinuation of chemo 
due to other reasons other than 
reactivation of HBV 
5 
 
 Raised renal parameters 3(one in each HCC,ca 
lung and stomach) 
 Febrile neutropenia with sepsis 2( one in breast and 
stomach) 
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 The age of the patients range from 18 to 64 yrs included in the 
study .median age was 52 yrs. Among 38 patients 11 patients were female 
and 27 male patients were in the study. There were 9 diabetic patients 
adequately controlled blood sugar with insulin and serially monitored 
during every chemotherapy cycles. All the patients were advised to 
changed to insulin even though adequately controlled with OHAs.  With 
the guidance of diabetologist all were put on insulin injections. All the 
diabetic patients were excluded of diabetic nephropathy and were 
monitored with urine microalbuniuria and blood urea and creatinine 
during every cycle while on cisplatin based chemotherapy. 
 Among the 38 patients 5 patients were known case of ischemic 
heart disease with normal LV   function. All those patients were on 
antianginal drugs . About 8 patients were hypertensive and 6 patients 
were on T. amlodipine and 2 patients were on T. enalapril and atenolol. 
About 5 patients gave past history of anti tuberculous treatment. Both the 
Hodgkin lymphoma patients received ATT at a local hospital prior to 
referral here. Two lung cancer patients also gave history of  ATT , one 
patient 10 yrs ago and another about 22 yrs ago. One carcinoma stomach 
patient gave history of ATT 5 yrs ago.   
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 About 16 patients gave past history of jaundice and 2 patients gave 
history twice episode of jaundice one within the past 2 yrs then. Both the 
patients with 2 episode of jaundice were diagnosed as hepatocellular 
carcinoma. Among the fourteen patients eight were diagnosed as 
carcinoma stomach  , three were carcinoma lung one breast cancer , one 
colon cancer and one carcinoma anal canal. All the 18 patients underwent 
native treatment during the jaundice. 
Table 3: comorbidities 
1. No of patients with diabetes mellitus 
controlled 
9 
2. Patients with hypertensive 8 
3. No of patients with IHD 5 
4. Previous history of jaundice 16 
 2 episodes of past history of jaundice 2 
 Hepatocelllar ca with prev h/o 
jaundice 
2 
 Carcinoma stomach 6 
 Carcinoma lung 4 
 Carcinoma breast 1 
 Carcinoma colon 1 
 ostoesarcoma 1 
 Carcinoma anal canal 1 
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 Among the 38 patients who underwent chemotherapy as per the 
study protocol, 8 patients developed reactivation. All the patients who 
developed reactivation presented with  jaundice with elevated serum 
transaminases. They were again tested for serological markers for 
Hepatitis B. All the patients were positive for HBe antigen and HBV 
DNA positive who were previously negative. 
Table 4: 
No Malignancy No of patients reactivated 
1. Hepatocellular carcinoma 2 
2. Carcinoma of breast 1 
3. Carcinoma stomach 2 
4. Periampullary carcinoma 1 
5. osteosarcoma 1 
6. Carcinoma lung 1 
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Table. 5 
LFT profile of the patients who had reactivation of HBV and serological 
markers 
No Patients Bilirubin 
total-
DB/IDB 
mg% 
SGOT 
IU/L 
SGP
T 
IU/L 
ALP 
IU/L
S. 
Album
in 
gm% 
ANTI 
HBc Ab 
HBe Ag HBV 
DNA 
1. HCC 6.7-4.3/2.4 420 650 300 4.2gm
% 
positive positive positive 
2. HCC 5.4-3.4/2 880 1040 550 3.0gm
% 
positive positive positive 
3. Ca 
stomach 
5.8-3.2/2.6 440 400 350 4gm% Positive  positive NA 
4. Ca 
stomach 
8.2-5.4/2.8 800 1250 550 3gm% positive positive positive 
5. Ca lung 4.5-2.5/2 400 350 500 4.5 Positive  positive NA 
6. Ca 
breast 
5.5-3.5/2 350 400 300 4 Positive  positive Positive 
7. Peri 
amp ca 
10-6.4/3.6 540 550 600 3.5 positive positive positive 
8. osteosa
rcoma 
3.5-2/1.5 300 550 800 2.8 Positive  positive positive 
 
 Among the 38 patients , 8 patients underwent reactivation of HBV. 
Malignancy taking in the study 2 patients with hepatocellular carcinoma, 
2 patients with carcinoma stomach underwent reactivation. One patient in 
each of ca breast, osteosarcoma, ca lung and periampullary carcinoma 
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forms the remaining. Among the four patients of hepatocellular 
carcinoma 2 patients underwent reactivation, 2 patients among the 7 ca 
stomach patients underwent reactivation, 1 patient among the 6 ca breast 
patients,1 among the 2 osteosarcoma patients and one patient among the 7 
ca lung patients underwent reactivation  Only one patient with 
periampullary carcinoma included in the study had reactivation of HBV. 
Table: 6 
S. 
No. 
Malignancy Patients in 
study 
Reactivation % 
1. Hepatocellular 
carcinoma 
4 2 50% 
2. Carcinoma stomach 7 2 28.56% 
3. Carcinoma breast 6 1 16.66% 
4. osteosarcoma 2 1 50% 
5. Carcinoma lung 7 1 14.28% 
6. Periampullary 
carcinoma 
1 1 100% 
 Total 38 8 21.05% 
  
 Among the 8 patients 7 patients received palliative chemotherapy 
for metastatic disease or advanced stage or relapse patients  . Only one 
carcinoma stomach patient received adjuvant chemotherapy underwent 
reactivation of HBV. 
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DISCUSSION 
 The reactivation of Hepatitis B virus in the patients receiving 
chemotherapy has been proven in many studies ,but most of the studies 
are involving the treatment of hematological malignancies and the use of 
Rituximab. In various studies the incidence of reactivation of Hepatitis b 
in  lymphoma(81-83) patients receiving chemotherapy is about 40%.the 
incidence of reactivation n patients receiving rituximab is about 60%. A 
study in Hong Kong in  breast cancer patients receiving chemotherapy 
with alkylating agents along with steroids has high incidence of about 
73%. 
 While comparing our study with the a study at Turkey(74) which 
had been done involving all solid tumors,in that study totally 59 patients 
of which 50 patients were of solid malignancy and 9 hematological 
malignancy patients,the incidence of reactivation was about 15%. 
In our study totally 38 patients were included in the study and the 
incidence of reactivation is about 21% and totally 8 patients got 
reactivated which is significant because of the morbidity  and mortality 
associated with reactivation of HBV and the delay in chemotherapy 
which may lead to progression of malignancy. Most of the patients got 
reactivation was treated for the metastatic disease with palliative 
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chemotherapy. Most of the patients got reactivated were treated with 
more immunosuppressive chemotherapy such as adriamycin and 
etoposide. Similarly many studies have shown that adriamycin based 
chemotherapy and steroids have shown increased incidence of 
reactivation of HBV. Most of the reactivation occurs between the second 
and fourth cycle of chemotherapy. There are few studies which showed 
late reactivation of hepatitis B virus even after completion of 
chemotherapy, but in our study none of the patients got reactivated after 3 
months of follow up, but a longer term of follow up must be needed.  In 
our study none of the patients had non hodgkins lymphoma in which most 
of the studies showed increased incidence of reactivation . 
 In our study all the 9 patients showed increased in the liver enzyme 
level as the earliest sign along with development of jaundice. So all the 
patients with Hepatitis S antigen positive  on immunosuppressive therapy 
should undergo regular monitoring of liver function tests for early 
detection of reactivation of HBV and can be treated earlier to prevent 
mortality. 
 As in the literature review among the solid malignancies 
hepatocellular carcinoma has highest incidence of reactivation of HBV 
about 70%, followed by breast cancer about 40-60% in various studies. In 
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our study too  out of 4 patients with hepatocellular carcinoma in the study 
2 patients underwent reactivation. 
 Similarly patients with metastatic disease undergoing 
chemotherapy with HBsAg positive has increased incidence of 
reactivation probably because of advanced nature of disease and 
increased cancer burden which may lead to immune suppression .Out of  
8 patients who had reactivation 7 patients underwent chemotherapy for 
metastatic or relapse disease. Age of the patient was not found to be 
significant in reactivation in our study. 
 As per our study the incidence of reactivation is about 21% even in 
the solid malignancies undergoing chemotherapy in patients with chronic 
HBs Ag  carriers, which is significant and all the patients should be 
started on lamivudine prophylaxis to prevent reactivation. There is  
another subset of patients who are HBc antibodies positive but HBs Ag 
negative(90) , patients had infection but not chronic carriers, can undergo 
reactivation during chemotherapy which has not been accounted in our 
study, needs further studies in solid malignancies whether to start 
lamivudine prophylaxis for that patients too will be useful. (91-93,95) 
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CONCLUSION 
FROM THE STUDY, we concluded that 
1. The overall incidence of chronic HBs antigen carrier state is about 
3.35% 
2. The incidence of reactivation of Hepatitis B virus in chronic HBs 
antigen patients receiving chemotherapy is 21% as we concluded 
from the study. 
3. Patients who are on adriamycin based chemotherapy for the solid 
malignancies also had increased incidence of reactivation of 
hepatits B virus in HBs antigen  chronic carriers. 
4. Since patients with solid malignancy in chronic carrier HBs antigen 
state had high incidence of reactivation, we suggest that those 
patients should be treated with prophylactic Lamivudine .  
 
Clinical Course of HBV  
Serology of HBV 
 
PROFORMA 
NAME:                                                     M.O.-No: 
AGE:                                                         SEX: 
ADDRESS:                                               OCCUPATION 
DETAILS OF MALIGNANCY: 
Malignancy –organ involved: 
Type: 
Stage: 
Principle of treatment: palliative/ curative/adjuvant/neoadjuvant/induction 
Chemo regimens/schedules: 
Chemotherapy cycle: 
CLINICAL FEATURES: 
Symptoms: 
H/O  present illness: 
Past history: DM/HT/ IHD/ PT/ BA/ COPD/ CKD/ DCLD/HIV 
                       H/O STEROIDS/ANY IMMUNOSUPPRESANTS   
                       H/O AUTO IMMUNE DISORDERS 
                       Prev H/O radiotherapy and any other malignancy/chemotherapy 
Personal history: 
                  Diet  
                   Smoking /Alcoholic 
                 Sexual history –PMC/ EMC                            SAFE/UNSAFE 
Family history: 
                  H/O malignancy in family   
                H/O HBV in family 
               H/o congenital immunodeficiency disorders 
Vitals: 
1. Pulse 
2. Temperature 
3. Weight\height 
4. BSA 
General Examination: 
                  Performance status: 
                  Conscious 
                  Orientation 
                  Febrile 
                  Pallor/ Cyanosis/Clubbing 
                  Jaundiced 
                  Pedal edema. / Gen lymphadenopathy 
Cardiovascular system: 
Respiratory system: 
Per abdomen ex: 
Central nervous system: 
Local examination: 
INVESTIGATIONS: 
CBC:    TC: 
            DC: 
            ESR: 
            HB% 
            PLATELETS 
RFT:  BUN: 
         CREATININE:   
LIVER FUNCTION TEST: 
          TOTAL BILIRUBIN 
           DIRECT/ INDIRECT 
             SGOT/ SGPT 
           S. ALKALINE PHOSPHOTASE 
           S. PROTEINS 
           ALBUMIN/GLOBULIN 
CHEST X-RAY: 
USG ABDOMEN: 
DIAGNOSTIC AND STAGING WORKUP FOR MALIGNANCY: 
SEROLOGICAL MARKERS: 
AT INITIATION OF CHEMOTHERAPY: 
        HBs Ag 
        ANTI HBc Ab    
        HBe Ag 
        HBV DNA 
       SEROLOGY FOR HIV 
       SEROLOGY FOR HCV 
CHEMO CYCLE-1 
          CHEMO REGIMEN: 
          REGIMEN/ PERIOD: 
          CBC/RFT/LFT 
CHEMO CYCLE-2 
CHEMO CYCLE-3 
CHEMO CYCLE-4 
CHEMOCYCLE-5 
CHEMOCYCLE-6 
OTHERS 
ONE MONTH AFTER CHEMOTHERAPY: 
         LFT 
         HBs Ag 
         HBe Ag 
         HBV DNA  
         ANTI HBc Ab 
TWO MONTHS AFTER CHEMOTHERAPY: 
        LFT 
       HBs Ag 
       HBe Ag 
       HBV DNA 
       ANTI HBc Ab         
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